Safety profile of new anticancer drugs

Bibliography

• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70
   PubMed Web of Science ®Google Scholar
• Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30:255-68
   PubMed Web of Science ®Google Scholar
• Hoag JB, Azizi A, Doherty TJ, Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009;28:103
   PubMedGoogle Scholar
• Yano S, Kondo K, Yamaguchi M, Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23:3639-50
   PubMed Web of Science ®Google Scholar
• Mascia F, Mariani V, Girolomini G, Blockade of the EGF receptor induces a deranged chemokine expression in keratonycites leading to enhanced skin inflammation. Am J Pathol 2003;163:303-12
   PubMed Web of Science ®Google Scholar
• Herbst RS, Lorusso PM, Purdom M, Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung cancer 2003;4:366-9
   PubMedGoogle Scholar
• Jacot W, Bessis D, Jorda E. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patient with solid tumors. Br J Dermatol 2004;151-238
   Google Scholar
• Sundermeyer ML, Lessin SR, Meropol NJ. Targeted therapies in colorectal cancer: complications and management. Curr Colorectal Cancer Rep 2006;2:125-33
   Google Scholar
• Perez-Soler R, Delord JP, Halpern A, HER1/EGFR inhibitor associated rash: future directions for management and investigation outcomes fromcombined with cisplatin and gemcitabine (GC) chemotherapy in advanced non small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004;23:617
   Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Clark GM, Perez-Soler R, Siu L, Rash severity is predictive of increased survival with erlotinib HCI. Proc Am Soc Clin Oncol 2003;22:196
   Web of Science ®Google Scholar
• Saltz L, Kies M Abbruzzese JL, The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204
   Web of Science ®Google Scholar
• Kris Mg, Natale RB, Herbst RS, Efficacy of gefitinib an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen F, Stadler WM, Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;21:2237-46
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Chachaoua A, Hammond L, Determinants of tumor response and survival with relotinib. J Clin Oncol 2004;22:3238-47
   PubMed Web of Science ®Google Scholar
• Bouche O, Brixi-Benmansour H, Bertin A, Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005;16:1171-2
   Google Scholar
• Boucher KW, Davidson K, Mirakkur B, Paronychia induced cetuximab, an antiepidermal growth factor receptor antibody. J Am Acad Dermatol 2002;45:632-3
   Google Scholar
• Dueland S, Sauer T, Lund-Johansen F, Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003;42:345-6
   PubMed Web of Science ®Google Scholar
• Mitchell EP, Lacouture M, Shearer H, Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2009;27(18 Suppl):, abstract CRA4027
   Web of Science ®Google Scholar
• Shepherd FA, Pereira JR, Ciuleanu TE, Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Boeck S, Vehling-Kaiser U, Waldschmidt D, Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs 2010;21:94-100
   Google Scholar
• Tsao MS, Sakurada A, Cutz JC, Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1 EGFR targeted agents:is there a silver living? J Clin Oncol 2005;23:5235-46
   PubMed Web of Science ®Google Scholar
• Hughes AN, O'Brien ME, Petty WJ, Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009;10:1220-6
   Google Scholar
• Razis E, Skarlos D, Briasoulis E, Treatment of non-small cell lung cancer with gefitinib (‘Iressa’, ZD1839): the Greek experience with a compassionate-use program. Anticancer Drugs 2005;16:191-8
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864-71
   PubMed Web of Science ®Google Scholar
• Mohamed MK, Ramalingam S, Lin Y, Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-5
   PubMed Web of Science ®Google Scholar
• Schutte W, Nagel S, Schaedlich S, Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the ‘Iressa’ expanded access program. Onkologie 2005;28:195-8
   PubMed Web of Science ®Google Scholar
• Li J, Karlsson MO, Brahmer J, Population pharmacokinetic (PK)-pharmacodynamic (PD) modelfor gefitinib in cancer patients. Proc Am Soc Clin Oncol 2005;41: abstract 3083
   Google Scholar
• Rudin CM, Liu W, Desai A, Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-27
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams GA, Sridhara R, FDA drug approval summary: gefitinib (ZD1839) tablets. Oncologist 2003;8:303-6
   PubMed Web of Science ®Google Scholar
• Liu V, White DA, Zakowski MF, Pulmonary toxicity associated with erlotinib. Chest 2007;132(3):1042-4
   PubMed Web of Science ®Google Scholar
• Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib. Saf Reminder JOP 2008;9:748-52
   Google Scholar
• Ho C, Davis J, Anderson F, Side effects related to cancer treatment: CASE 1. hepatitis following treatment with gefitinib. J Clin Oncol 2005;23:8531-3
   PubMed Web of Science ®Google Scholar
• Carlini P, Papaldo P, Fabi A, Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450? J Clin Oncol 2006;24:e60-1
   PubMed Web of Science ®Google Scholar
• Masutani K, Fujisaki K, Maeda H, Tubulointerstitial nephritis and IGA nephropathy in a patient with advanced lung cancer treated with long-term gefetinib. Clin Exp Nephrol 2008;12:398-402
   PubMed Web of Science ®Google Scholar
• Kumasaka R, Nakamura N, Shirato K, Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol 2004;22:2504-5
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25(13):1658-64
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, The anti-inflammator effects of omalizumab confirm the central role in IGE in allergic inflammation. J Allergy Clin immunol 2005;115:459-65
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S, The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24
   PubMed Web of Science ®Google Scholar
• Cook-Bruns N. Retrospective analysis of the safety of herceptin immunotherapy in metastatic breast cancer. Oncology 2001;61:58-66
   PubMed Web of Science ®Google Scholar
• Omalizumab (marketed as Xolair) information. Food and drugs Administration, Center for Drug Evaluation and Research; Rockville, MD: 2007
   Google Scholar
• Erbitux (cetuximab). Imclone Systems Inc. and Bristol-Myers Squibb; New York: 2007. Drug product label
   Google Scholar
• Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-6
   PubMed Web of Science ®Google Scholar
• Imclone Systems Inc. NYN, Brystol-Myers Squibb Co PN: Erbitux (Cetuximab) package Insert. 2008
   Google Scholar
• Schwartzberg LS, Stepanski EJ, Walker MS, Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer 2009;1:91-8
   Google Scholar
• Chung CH, Mirakhur B, Chan E, Cetuximab-induced anaphylaxis and IGE specific for galactose-alpha-1, 3-galactose. N Engl J Med 2008;13:1109-17
   Google Scholar
• Van Cutsem E, Köhne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;2:1408-17
   Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;15:2040-8
   Google Scholar
• Schrag D, Chung KY, Flombaum C, Saltz L. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005;97(16):1221-4
   PubMed Web of Science ®Google Scholar
• Mc Evoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-system pharmacists, Inc. p. 977-80
   Google Scholar
• Melichar B, Nemcova I. Eye complications of cetuximab therapy. Eur J Cancer Care 2007;16:439-43
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Tahara M, Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. Int J Clin Oncol 2009;14:307-14
   PubMed Web of Science ®Google Scholar
• Schechter AL, Hung MC, Vaidyanathan L, The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-8
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 2003;9:5078-84
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9
   PubMed Web of Science ®Google Scholar
• Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999;18:465-71
   PubMed Web of Science ®Google Scholar
• Smith IE. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anticancer Drugs 2001;12:3-10
   Google Scholar
• Masataka S, Yoshinori I, Keiichiro T, Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with her-2/NEU-overexpressing metastatic breast cancer. Tumori 2004;90:40-43
   Google Scholar
• Seidman A, Hudis C, Pierri MK, Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215-21
   PubMed Web of Science ®Google Scholar
• Theodoulou M, Batist G, Campos S, Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer 2009;9:101-7
   PubMed Web of Science ®Google Scholar
• Erickson SL, O'Shea KS, Ghaboosi N, ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development 1997;124:4999-5011
   PubMed Web of Science ®Google Scholar
• Crone SA, Zhao YY, Fan L, ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland- Jones B, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Eiermann W, Robert N, Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2005;94:S5
   Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20
   PubMed Web of Science ®Google Scholar
• Viani GA, Afonso SL, Stefano EJ, Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007;7:153
   PubMed Web of Science ®Google Scholar
• Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:3525-33
   PubMed Web of Science ®Google Scholar
• Vahib B, Marik P. Pulmonary complications of novel antineoplasic agents for solid tumors. Chest 2008;133:528-38
   PubMed Web of Science ®Google Scholar
• Pepels MJ, Boomars KA, van Kimmenade R, Hupperets PS. Life-threatening interstitial lung disease associated with trastuzumab: case report. Breast Cancer Res Treat 2009;113:609-12
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Parsa V, Liu CY, Fontana JA. Trastuzumab-induced hepatotoxicity. Ann Pharmacother 2008;42:1497-501
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94
   PubMed Web of Science ®Google Scholar
• Wood ER, Truesdale AT, McDonald OB, A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-9
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2- overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Kaplan EH, Franco SX, A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004;22(Suppl 14):, abstract 3006
   Web of Science ®Google Scholar
• Kaplan EH, Jones CM, Berger MS. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. J Clin Oncol 2003;22: abstract 981
   Web of Science ®Google Scholar
• Burstein H, Storniolo AM, Franco S, A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumabcontaining regimens. Ann Oncol 2004;15(Suppl 3): abstract 1040
   Google Scholar
• Trudeau M, Johnston S, Kaufman, Lapatinib (Tyverb) monotherapy in patients with recurrent inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Ann Oncol 2006;17(Suppl 9):ix69
   Google Scholar
• Cristofanilli M, Boussen H, Baselga J. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer. Breast Cancer Res 2006;100(Suppl 1):S5
   Google Scholar
• Geyer CE, Martin A, Newstat B, Lapadnib (L) plus capecitabine (C) in HER2+advanced breast cancer (ABC): genomic and updated efficacy data. J Clin Oncol 2007;25(40 Suppl): abstract 1035
   PubMedGoogle Scholar
• Crown JP, Burris HA III, Boyle F, Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;112:317-25
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Laabs SM, Koehler M, Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009;114(3):485-93
   PubMed Web of Science ®Google Scholar
• Perez EA, Byrne JA, Isaac W, Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol 2006;17(Suppl 9):ix70-
   Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, Di Tomaso E, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-3
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95
   PubMed Web of Science ®Google Scholar
• Shaheen RM, Tseng WW, Davis DW, Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001;61:1464-8
   PubMed Web of Science ®Google Scholar
• Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10:6388S-92S
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25:2993-5
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-Carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006;14:2542-50
   Google Scholar
• Miller KD, Wang M, Gralow J, A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94:3a
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
   PubMed Web of Science ®Google Scholar
• Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201
   PubMedGoogle Scholar
• Miller KD, Chap LI, Holmes FA, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
   PubMed Web of Science ®Google Scholar
• Appel LJ, Moore TJ, Obarzanek E, A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997;336:1117-24
   PubMed Web of Science ®Google Scholar
• Izzedine H, Ederhy S, Goldwasser F, Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009;20:807-15
   PubMed Web of Science ®Google Scholar
• Halimi JM, Azizi M, Bobrie G, Vascular and renal effects of anti-angiogenic therapy. Nephrol Ther 2008;4:602-15
   PubMed Web of Science ®Google Scholar
• T Kamba, McDonald DM. Mechanisms of adverse effects of anti VEGF therapy for cancer. Br J Cancer 2007;96:1788-95
   PubMed Web of Science ®Google Scholar
• Skillings JR, Johnson DH, Miller K, Arterial thromboembolic events ATEs in a pooled analysis of 5 randomized, controlled trials RCTs of bevacizumab (BV) woth chemotherapy. J Clin Oncol 2005;23:3019
   Web of Science ®Google Scholar
• D'Adamo DR, Anderson SE, Albritton K, Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-42
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Langmuir VK, Sledge GW, A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003;30:117-24
   PubMed Web of Science ®Google Scholar
• Wedam SB, Low JA, Yang SX, Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24:769-77
   PubMed Web of Science ®Google Scholar
• Frangie C, Lechaufeur C, Medioni J, Renal thrombotic microangiopathy caused by antiVEGF–antibody treatment for metastatic renal cell carcinoma. Lancet Oncol 2007;8:177-8
   PubMed Web of Science ®Google Scholar
• Roncone D, Satoskar A, Nadasdy T, Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007;3:287-93
   PubMedGoogle Scholar
• Eremina V, Jefferson JA, Kowalewska J, VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008 358: 1129-36
   PubMed Web of Science ®Google Scholar
• Bates DO, Jones RO. The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2003;2:107-20
   PubMedGoogle Scholar
• Lu JF, Bruno R, Eppler S, Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62:779-8
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T, Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-80
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny W, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel woth carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non small cell lung cancer. J Clin Oncol 2004;22:2184-91
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33:S26-34
   PubMed Web of Science ®Google Scholar
• Hedrick E, Kozloff M, Hainsworth J, A Safety of bevacizumab plus chemotherapy as first line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRITE). J Clin Oncol 2006;24:3536
   Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006;354:980-2; discussion 980-2
   PubMed Web of Science ®Google Scholar
• Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006;63:1475-8
   PubMed Web of Science ®Google Scholar
• Govindarajan R, Adusumilli J, Baxter DL, Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006;24:e48
   Google Scholar
• Martín G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007;25:3559
   PubMed Web of Science ®Google Scholar
• Abrams TJ, Lee LB, Murray LJ, SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• George S, Blay JY, Casali PG, Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
   PubMed Web of Science ®Google Scholar
• Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084-96
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-9
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R, Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-73
   PubMed Web of Science ®Google Scholar
• Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;8:465-77
   Google Scholar
• Motzer RJ, Rini BI, Bukowski RM, Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24
   PubMed Web of Science ®Google Scholar
• Bollee G, Patey N, Cazajous G, Thrombotic microangiopathy secondary to VEGF patway inhibition by sunitinib. Nephrol Dial Transplant 2009;24:682-5
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbado C, Vera K, Pharmacokinetic, and antitumor activity of SU11248, a novel oral multitargeted tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35
   PubMed Web of Science ®Google Scholar
• Wood LS. Managing the side effects of sorafenib and sunitinib. Community Oncol 2006;3:558-62
   Google Scholar
• Escudier B, Szczylik C, Eisen T, Randomized phase II trial of the Raf Kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005;23:4510a
   Web of Science ®Google Scholar
• Awada A, Handlisz A, Gil T, Phase I safety and pharmacokinetics of BAY-439006 administered for 21 days on/7days off in patients with advanced refractory solid tumors. Br J Cancer 2005;92:1855-61
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, The safety and pharmacokinetics of multitargeted tyrosine kinase inhibitor (including Raf kinase and VEGF kinase), BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80
   PubMed Web of Science ®Google Scholar
• Moore MF, Hirte HW, Siu L, Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA, Phase I clinical and pharmacokinetics study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with an expanded cohort in advanced refractory solid tumors. J Clin Oncol 2005;23:965-72
   PubMed Web of Science ®Google Scholar
• Siu L, Awada A, Takimoto CH, Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM, Phase II placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Sorafenib in advanced melanoma: a phase II randomized discontinuation trial analysis. Br J Cancer 2006;95:581-6
   PubMed Web of Science ®Google Scholar
• Richly H, Henning BF, Kupsch P, Results of a phase I trial of sorafenib (Bay 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17:866-73
   PubMed Web of Science ®Google Scholar
• Robert C, Soria JC, SPatz A, Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet 2005;6:491-500
   PubMed Web of Science ®Google Scholar
• Invanyi P, Winkler T, Ganser A, Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. Dtsch Arztebl Int 2008;105:232-7
   PubMed Web of Science ®Google Scholar
• Yang CH, Lin WC, Chuang CK, Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158:592-6
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P, Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81-3
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Soulieres D, Wong R, Sunitinib therapy for metastatic renal cell carcinoma: recommandations for management of side effects. Can Urol Assoc 2007;1:S41-54
   PubMed Web of Science ®Google Scholar
• Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 2004;6:547-52
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-21
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, Efficacy and safety of imatinib mesylate in Advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
   PubMed Web of Science ®Google Scholar
• Brouard M, Sauart JH. Cutaneous reactions STI571. N Engl J Med 2001;345:618-9
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Sakai F, Kudoh S, Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib. Leukemia 2006;20:1162-4
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, Efficacy and safety of a specific inhibitor of the BCR ABL tyrosine Kinase in chronic myeloid leukaemia. N Engl J Med 2001;344(14):1031-7
   PubMed Web of Science ®Google Scholar
• Chevallier P, Hunault-Berger M, Larosa F, A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: the AFR-15 trial. Leuk Res 2009;33:1124-6
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Billemont B, Rixe O. Renal toxicity of targeted therapies. Targ Oncol 2009;4:121-33
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16
   PubMed Web of Science ®Google Scholar
• Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-7
   PubMed Web of Science ®Google Scholar
• Breccia M, Cannella L, Frustaci A, Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience. Leuk Res 2008;32:835-6
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Kotasek D, Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007;43:974-8
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32
   PubMed Web of Science ®Google Scholar
• Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103:253-62
   PubMed Web of Science ®Google Scholar
• Skotnicki JS, Leone CL, Smith AL, Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin Cancer Res 2001;7(Suppl):3749S-50S
   Google Scholar
• Hudes G, Carducci M, Tomczak P, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM, Randomized phase ii study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18
   PubMed Web of Science ®Google Scholar
• Raymond E, Alexandre J, Faivre S, Safety and pharmacokinetis of escalated doses of weekly intravenous infection of CCI 779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Szczylik C, Feingold J, Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58
   PubMed Web of Science ®Google Scholar
• Lorber MI, Mulgaonkar S, Butt KM, Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244-52
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
   PubMed Web of Science ®Google Scholar
• Kapoor A. Inhibition of mtor in kidney cancer. Curr Oncol 2009;16(Suppl 1):S33-9
   Google Scholar
• Kube R, Meyer F, Bien N, Surgical management of bevacizumab-associated peritonitis due to perforation. Zentralbl Chir 2009;134:462-7
   PubMed Web of Science ®Google Scholar
• Bellmunt J. Future developments in renal cell carcinoma. Ann Oncol 2009;20:13-7
   Google Scholar
• Storniolo AM, Pegram MD, Overmoyer B, Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008;26:3317-23
   PubMed Web of Science ®Google Scholar
• Raefsky E, Castillo R, Lahiry A, Phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+locally advanced breast cancer. J Clin Oncol 2008;26(20 Suppl):, abstract 627
   Google Scholar
• Rini BI, Garcia JA, Cooney MM, A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15:6277-83
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-72
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Lin NU, Carey LA, Liu MC, Phase II trial of lapatinib for brain metastases in patients with HER2 breast cancer. J Clin Oncol 2006;24(Suppl 18):3S
   Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90
   PubMed Web of Science ®Google Scholar
• Fingar DC, Richardson CJ, Tee AR, mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation factor 4E. Mol Cell Biol 2004;24:200-16
   PubMed Web of Science ®Google Scholar
• Harding MW. Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003;9:2882-6
   PubMed Web of Science ®Google Scholar